HIV Prevention Drug-Lenacapavir
By Tosin Ogunrinde
South Africa has launched a groundbreaking HIV prevention drug, lenacapavir, which is administered twice a year and has shown to reduce the risk of HIV transmission by more than 99.9%. This makes it functionally akin to a powerful vaccine. The rollout marks a significant milestone in the fight against HIV, particularly in Africa, which has the world’s highest HIV burden.
The initial rollout is being overseen by Wits University’s research unit, funded by Unitaid, and is expected to expand nationally next year. Lenacapavir is a long-acting injectable antiretroviral medicine given every six months for HIV prevention. In clinical trials, it was found to be safe and effective, with 96-100% reduction in HIV acquisition compared with background rates.
The introduction of lenacapavir is particularly significant for people who struggle to adhere to daily pill regimens. Deputy President Paul Mashatile hailed the drug as a symbol of what becomes possible when science, political will, and community demand meet. He emphasized the importance of making the drug accessible, affordable, and locally produced.
The cost of lenacapavir was initially projected to be around $28,000 per person annually in the United States. However, a pricing deal has reduced the cost to approximately $40 per year, making it more affordable in low- and middle-income countries. Gilead Sciences has committed to providing lenacapavir at no profit to two million people in high-burden countries over three years.
South Africa’s Health Minister, Aaron Motsoaledi, said the country is working with relevant stakeholders to make lenacapavir available to vulnerable populations, especially adolescent girls, young women, and pregnant and breastfeeding women. The World Health Organization has described lenacapavir as a “significant breakthrough” in HIV prevention.
The launch of lenacapavir is a major step forward in the fight against HIV, and its success will depend on widespread access and uptake. As UNAIDS executive director Winnie Byanyima said, “If you don’t care about those lives, at least you care about the profit! Bring the drug here.
